Cargando…

Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study

OBJECTIVES: This study aims to determine the proportion of initial cardiometabolic assessment and its predicting factors in adults with schizophrenia, bipolar disorder or other related diagnoses for whom a second-generation antipsychotic was prescribed in the hospital setting. DESIGN: Cross-sectiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontaine, Jennifer, Chin, Evelyn, Provencher, Jean-François, Rainone, Anthony, Wazzan, Dana, Roy, Carmella, Rej, Soham, Lordkipanidze, Marie, Dagenais-Beaulé, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006820/
https://www.ncbi.nlm.nih.gov/pubmed/35414553
http://dx.doi.org/10.1136/bmjopen-2021-055454
_version_ 1784686741050884096
author Fontaine, Jennifer
Chin, Evelyn
Provencher, Jean-François
Rainone, Anthony
Wazzan, Dana
Roy, Carmella
Rej, Soham
Lordkipanidze, Marie
Dagenais-Beaulé, Vincent
author_facet Fontaine, Jennifer
Chin, Evelyn
Provencher, Jean-François
Rainone, Anthony
Wazzan, Dana
Roy, Carmella
Rej, Soham
Lordkipanidze, Marie
Dagenais-Beaulé, Vincent
author_sort Fontaine, Jennifer
collection PubMed
description OBJECTIVES: This study aims to determine the proportion of initial cardiometabolic assessment and its predicting factors in adults with schizophrenia, bipolar disorder or other related diagnoses for whom a second-generation antipsychotic was prescribed in the hospital setting. DESIGN: Cross-sectional study. SETTING: The psychiatry unit of a Canadian tertiary care teaching hospital in Montreal, Canada. PARTICIPANTS: 402 patients with aforementioned disorders who initiated, restarted or switched to one of the following antipsychotics: clozapine, olanzapine, risperidone, paliperidone or quetiapine, between 2013 and 2016. PRIMARY OUTCOME MEASURES: We assessed the proportion of cardiometabolic parameters monitored. SECONDARY OUTCOME MEASURES: We identified predictors that influence the monitoring of cardiometabolic parameters and we assessed the proportion of adequate interventions following the screening of uncontrolled blood pressure and fasting glucose or glycated haemoglobin (HbA1c) results. RESULTS: Only 37.3% of patients received monitoring for at least three cardiometabolic parameters. Blood pressure was assessed in 99.8% of patients; lipid profile in 24.4%; fasting glucose or HbA1c in 33.3% and weight or body mass index in 97.8% of patients while waist circumference was assessed in 4.5% of patients. For patients with abnormal blood pressure and glycaemic values, 42.3% and 41.2% subsequent interventions were done, respectively. The study highlighted the psychiatric diagnosis (substance induced disorder OR 0.06 95% CI 0.00 to 0.44), the presence of a court-ordered treatment (OR 0.79 95% CI 0.35 to 1.79) and the treating psychiatrist (up to OR 34.0 95% CI 16.2 to 140.7) as predictors of cardiometabolic monitoring. CONCLUSIONS: This study reports suboptimal baseline cardiometabolic monitoring of patients taking an antipsychotic in a Canadian hospital. Optimising collaboration within a multidisciplinary team may increase cardiometabolic monitoring.
format Online
Article
Text
id pubmed-9006820
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90068202022-05-02 Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study Fontaine, Jennifer Chin, Evelyn Provencher, Jean-François Rainone, Anthony Wazzan, Dana Roy, Carmella Rej, Soham Lordkipanidze, Marie Dagenais-Beaulé, Vincent BMJ Open Cardiovascular Medicine OBJECTIVES: This study aims to determine the proportion of initial cardiometabolic assessment and its predicting factors in adults with schizophrenia, bipolar disorder or other related diagnoses for whom a second-generation antipsychotic was prescribed in the hospital setting. DESIGN: Cross-sectional study. SETTING: The psychiatry unit of a Canadian tertiary care teaching hospital in Montreal, Canada. PARTICIPANTS: 402 patients with aforementioned disorders who initiated, restarted or switched to one of the following antipsychotics: clozapine, olanzapine, risperidone, paliperidone or quetiapine, between 2013 and 2016. PRIMARY OUTCOME MEASURES: We assessed the proportion of cardiometabolic parameters monitored. SECONDARY OUTCOME MEASURES: We identified predictors that influence the monitoring of cardiometabolic parameters and we assessed the proportion of adequate interventions following the screening of uncontrolled blood pressure and fasting glucose or glycated haemoglobin (HbA1c) results. RESULTS: Only 37.3% of patients received monitoring for at least three cardiometabolic parameters. Blood pressure was assessed in 99.8% of patients; lipid profile in 24.4%; fasting glucose or HbA1c in 33.3% and weight or body mass index in 97.8% of patients while waist circumference was assessed in 4.5% of patients. For patients with abnormal blood pressure and glycaemic values, 42.3% and 41.2% subsequent interventions were done, respectively. The study highlighted the psychiatric diagnosis (substance induced disorder OR 0.06 95% CI 0.00 to 0.44), the presence of a court-ordered treatment (OR 0.79 95% CI 0.35 to 1.79) and the treating psychiatrist (up to OR 34.0 95% CI 16.2 to 140.7) as predictors of cardiometabolic monitoring. CONCLUSIONS: This study reports suboptimal baseline cardiometabolic monitoring of patients taking an antipsychotic in a Canadian hospital. Optimising collaboration within a multidisciplinary team may increase cardiometabolic monitoring. BMJ Publishing Group 2022-04-11 /pmc/articles/PMC9006820/ /pubmed/35414553 http://dx.doi.org/10.1136/bmjopen-2021-055454 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cardiovascular Medicine
Fontaine, Jennifer
Chin, Evelyn
Provencher, Jean-François
Rainone, Anthony
Wazzan, Dana
Roy, Carmella
Rej, Soham
Lordkipanidze, Marie
Dagenais-Beaulé, Vincent
Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
title Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
title_full Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
title_fullStr Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
title_full_unstemmed Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
title_short Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
title_sort assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: the cami-sga study – a cross-sectional study
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006820/
https://www.ncbi.nlm.nih.gov/pubmed/35414553
http://dx.doi.org/10.1136/bmjopen-2021-055454
work_keys_str_mv AT fontainejennifer assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy
AT chinevelyn assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy
AT provencherjeanfrancois assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy
AT rainoneanthony assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy
AT wazzandana assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy
AT roycarmella assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy
AT rejsoham assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy
AT lordkipanidzemarie assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy
AT dagenaisbeaulevincent assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy